表紙
市場調查報告書
商品編碼
1000970

尿路感染的全球市場:按藥物類別,臨床指徵,按最終用戶市場調查進行的預測(∼2025年)),新型冠狀病毒肺炎(COVID-19)

Urinary Tract Infection Market Research Report by Drug Class, by Clinical Indication, by End User, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

出版日期: | 出版商: 360iResearch LLP | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

全球尿路感染市場預計將從2020年的712.798億美元增長到2025年底的984.814百萬美元。

預計COVID-19將在預測期內對行業增長產生長期影響,因為這是無與倫比的全球公共衛生突發事件,幾乎影響了每個行業。我們正在進行的研究擴大了研究框架,以確保它包括潛在的COVID-19問題和潛在的未來路徑。該調查提供了有關COVID-19的見解,並考慮了消費者行為和需求,購買模式,供應鏈改路,當前市場勢力動態以及政府的主要干預措施的變化。更新後的調查提供了見解,分析,估計和預測,其中考慮了COVID-19對市場的影響。

本報告調查了尿路感染的全球市場,市場概況,市場增長和抑制因素的分析,市場機會,COVID-19的影響,藥物類別,臨床適應症,最終用戶,它提供了諸如區域性的系統信息市場規模趨勢和預測,競爭狀況以及主要公司的概況。

目錄

第1章簡介

  • 調查目的
  • 市場細分和覆蓋範圍
  • 考慮調查的年份
  • 貨幣和價格
  • 語言
  • 限制
  • 利益相關者

第2章調查方法

  • 調查過程
    • 定義:調查目的
    • 決策:調查設計
    • 準備:測量設備
    • 集合:數據源
    • 分析:數據解釋
    • 公式:數據驗證
    • 已發佈:調查報告
    • 重複:報告更新
  • 進行調查
    • 開始:調查過程
    • 計劃:創建調查計劃
    • 執行:進行調查
    • 驗證:發現和分析
    • 出版物:調查報告
  • 調查結果

第3章執行摘要

  • 市場前景
  • 藥品類別展望
  • 臨床適應症的前景
  • 最終用戶展望
  • 區域展望
  • 競爭對手展望

第4章市場概述

  • COVID-19的累積效果

第5章市場洞察

  • 市場動態
    • 促進因素
    • 抑製器
    • 市場機會
    • 挑戰
  • 搬運工五力分析
    • 新進入者的威脅
    • 替代威脅
    • 客戶的議價能力
    • 供應商的談判能力
    • 行業競爭

第6章,按毒品類別

  • 氨基糖甘
  • Azole
  • 奎諾酮
  • B-內□胺

通過臨床適應症第7章

  • 膀胱炎
  • 腎盂腎炎
  • 尿道炎

最終用戶第8章

  • 醫院
  • 自我管理

第9章美洲

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區

  • 澳大利亞
  • 中國
  • 印度
  • 印度尼西亞
  • 日本
  • 馬來西亞
  • 菲律賓
  • 韓國
  • 泰國

第11章歐洲,中東/非洲

  • 法國
  • 德國
  • 意大利
  • 荷蘭
  • 卡塔爾
  • 俄羅斯
  • 沙特阿拉伯
  • 南非
  • 西班牙
  • 阿拉伯聯合酋長國
  • 英國

第12章競爭情況

  • FPNV定位矩陣
    • 象限
    • 經營策略
    • 產品滿意度
  • 市場排名分析
  • 市場份額分析
  • 競爭性SWOT分析
  • 衝突情況
    • 併購
    • 協議,合作和夥伴關係
    • 推出和增強新產品
    • 投融資
    • 獎項,獎項,擴展

第13章企業可用性概況

  • Allergan plc
  • AstraZeneca plc
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Cipla Inc.
  • Eli Lilly and Company,
  • F. Hoffmann La Roche Ltd
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Merck & Co., Inc.
  • Mindray Medical International Limited
  • Mylan N.V.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Siemens Healthcare
  • Sun Pharmaceuticals Ltd.
  • Teva Pharmaceuticals
  • Urit Medical Electronic Group Co., Ltd.

第14章附錄

  • 討論指南
  • 許可證和價格
目錄
Product Code: MRR-034B50030336

The Global Urinary Tract Infection Market size was estimated at USD 7,127.98 Million in 2020 and expected to reach USD 7,583.25 Million in 2021, at a Compound Annual Growth Rate (CAGR) 6.72% to reach USD 10,533.55 Million by 2026.

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Urinary Tract Infection to forecast the revenues and analyze the trends in each of the following sub-markets:

  • Based on Drug Class, the Urinary Tract Infection Market was studied across Aminoglycosides, Azoles, Quinolones, and B-lactam.
  • Based on Clinical Indication, the Urinary Tract Infection Market was studied across Cystitis, Pyelonephritis, and Urethritis.
  • Based on End User, the Urinary Tract Infection Market was studied across Hospitals and Self-Administered.
  • Based on Geography, the Urinary Tract Infection Market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific is further studied across China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Urinary Tract Infection Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Urinary Tract Infection Market, including Allergan plc, AstraZeneca plc, Bayer AG, Boehringer Ingelheim GmbH, Cipla Inc., Eli Lilly and Company,, F. Hoffmann La Roche Ltd, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co. Inc., Merck & Co., Inc., Mindray Medical International Limited, Mylan N.V., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Siemens Healthcare, Sun Pharmaceuticals Ltd., Teva Pharmaceuticals, and Urit Medical Electronic Group Co., Ltd..

The report provides insights on the following pointers:

  • 1. Market Penetration: Provides comprehensive information on the market offered by the key players
  • 2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
  • 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
  • 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
  • 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

  • 1. What is the market size and forecast of the Global Urinary Tract Infection Market?
  • 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Urinary Tract Infection Market during the forecast period?
  • 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Urinary Tract Infection Market?
  • 4. What is the competitive strategic window for opportunities in the Global Urinary Tract Infection Market?
  • 5. What are the technology trends and regulatory frameworks in the Global Urinary Tract Infection Market?
  • 6. What is the market share of the leading vendors in the Global Urinary Tract Infection Market?
  • 7. What modes and strategic moves are considered suitable for entering the Global Urinary Tract Infection Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

  • 3.1. Introduction
  • 3.2. Market Outlook
  • 3.3. Drug Class Outlook
  • 3.4. Clinical Indication Outlook
  • 3.5. End User Outlook
  • 3.6. Geography Outlook
  • 3.7. Competitor Outlook

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of diabetes and kidney stones
      • 5.1.1.2. Rise in the awareness among people regarding urinary tract infections owing to rising healthcare expenditure
      • 5.1.1.3. Emergence of portable and battery-operated urinary tract infections devices
    • 5.1.2. Restraints
      • 5.1.2.1. Complicated regulated monitoring
    • 5.1.3. Opportunities
      • 5.1.3.1. Increase in adoption of urinary tract infections in emerging economies
      • 5.1.3.2. Rise in R&D of a novel class of antibiotics for urinary tract infections
    • 5.1.4. Challenges
      • 5.1.4.1. Complex clinical trials for designing antibacterial drugs that require an informative, ethical, and scientific approach
  • 5.2. Cumulative Impact of COVID-19
  • 5.3. Porters Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry

6. Urinary Tract Infection Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Aminoglycosides
  • 6.3. Azoles
  • 6.4. Quinolones
  • 6.5. B-lactam

7. Urinary Tract Infection Market, by Clinical Indication

  • 7.1. Introduction
  • 7.2. Cystitis
  • 7.3. Pyelonephritis
  • 7.4. Urethritis

8. Urinary Tract Infection Market, by End User

  • 8.1. Introduction
  • 8.2. Hospitals
  • 8.3. Self-Administered

9. Americas Urinary Tract Infection Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States
    • 9.6.1. California
    • 9.6.2. Florida
    • 9.6.3. Illinois
    • 9.6.4. New York
    • 9.6.5. Ohio
    • 9.6.6. Pennsylvania
    • 9.6.7. Texas

10. Asia-Pacific Urinary Tract Infection Market

  • 10.1. Introduction
  • 10.2. China
  • 10.3. India
  • 10.4. Indonesia
  • 10.5. Japan
  • 10.6. Malaysia
  • 10.7. Philippines
  • 10.8. South Korea
  • 10.9. Thailand

11. Europe, Middle East & Africa Urinary Tract Infection Market

  • 11.1. Introduction
  • 11.2. France
  • 11.3. Germany
  • 11.4. Italy
  • 11.5. Netherlands
  • 11.6. Qatar
  • 11.7. Russia
  • 11.8. Saudi Arabia
  • 11.9. South Africa
  • 11.10. Spain
  • 11.11. United Arab Emirates
  • 11.12. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
    • 12.1.1. Quadrants
    • 12.1.2. Business Strategy
    • 12.1.3. Product Satisfaction
  • 12.2. Market Ranking Analysis
  • 12.3. Market Share Analysis, By Quadrant
  • 12.4. Market Share Analysis, By Company
  • 12.5. Competitive Scenario
    • 12.5.1. Merger & Acquisition
    • 12.5.2. Agreement, Collaboration, & Partnership
    • 12.5.3. New Product Launch & Enhancement
    • 12.5.4. Investment & Funding
    • 12.5.5. Award, Recognition, & Expansion

13. Company Usability Profiles

  • 13.1. Allergan plc
  • 13.2. AstraZeneca plc
  • 13.3. Bayer AG
  • 13.4. Boehringer Ingelheim GmbH
  • 13.5. Cipla Inc.
  • 13.6. Eli Lilly and Company,
  • 13.7. F. Hoffmann La Roche Ltd
  • 13.8. GlaxoSmithKline plc
  • 13.9. Johnson & Johnson
  • 13.10. Merck & Co. Inc.
  • 13.11. Merck & Co., Inc.
  • 13.12. Mindray Medical International Limited
  • 13.13. Mylan N.V.
  • 13.14. Novartis AG
  • 13.15. Novo Nordisk A/S
  • 13.16. Pfizer Inc.
  • 13.17. Siemens Healthcare
  • 13.18. Sun Pharmaceuticals Ltd.
  • 13.19. Teva Pharmaceuticals
  • 13.20. Urit Medical Electronic Group Co., Ltd.

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing
  • 14.3. Contact Details

LIST OF FIGURES

  • FIGURE 1. GLOBAL URINARY TRACT INFECTION MARKET SIZE, 2020 VS 2026 (USD MILLION)
  • FIGURE 2. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2020 (USD MILLION)
  • FIGURE 3. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2020 (USD MILLION)
  • FIGURE 4. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2020 (USD MILLION)
  • FIGURE 5. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
  • FIGURE 6. GLOBAL URINARY TRACT INFECTION MARKET: MARKET DYNAMICS
  • FIGURE 7. GLOBAL URINARY TRACT INFECTION MARKET: PORTERS FIVE FORCES ANALYSIS
  • FIGURE 8. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2020 VS 2026 (%)
  • FIGURE 9. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2020 VS 2026 (USD MILLION)
  • FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2026
  • FIGURE 11. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2026 (USD MILLION)
  • FIGURE 12. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY AMINOGLYCOSIDES, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 13. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY AZOLES, 2018-2026 (USD MILLION)
  • FIGURE 14. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY AZOLES, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 15. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY QUINOLONES, 2018-2026 (USD MILLION)
  • FIGURE 16. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY QUINOLONES, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 17. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY B-LACTAM, 2018-2026 (USD MILLION)
  • FIGURE 18. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY B-LACTAM, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 19. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2020 VS 2026 (%)
  • FIGURE 20. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2020 VS 2026 (USD MILLION)
  • FIGURE 21. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2026
  • FIGURE 22. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CYSTITIS, 2018-2026 (USD MILLION)
  • FIGURE 23. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CYSTITIS, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 24. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PYELONEPHRITIS, 2018-2026 (USD MILLION)
  • FIGURE 25. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PYELONEPHRITIS, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 26. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY URETHRITIS, 2018-2026 (USD MILLION)
  • FIGURE 27. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY URETHRITIS, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 28. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2020 VS 2026 (%)
  • FIGURE 29. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2020 VS 2026 (USD MILLION)
  • FIGURE 30. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2026
  • FIGURE 31. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY HOSPITALS, 2018-2026 (USD MILLION)
  • FIGURE 32. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY HOSPITALS, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 33. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY SELF-ADMINISTERED, 2018-2026 (USD MILLION)
  • FIGURE 34. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY SELF-ADMINISTERED, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 35. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 36. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 37. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 38. ARGENTINA URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 39. BRAZIL URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 40. CANADA URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 41. MEXICO URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 42. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 43. CALIFORNIA URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 44. FLORIDA URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 45. ILLINOIS URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 46. NEW YORK URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 47. OHIO URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 48. PENNSYLVANIA URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 49. TEXAS URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 50. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 51. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 52. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 53. CHINA URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 54. INDIA URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 55. INDONESIA URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 56. JAPAN URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 57. MALAYSIA URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 58. PHILIPPINES URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 59. SOUTH KOREA URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 60. THAILAND URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 61. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 62. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 63. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 64. FRANCE URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 65. GERMANY URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 66. ITALY URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 67. NETHERLANDS URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 68. QATAR URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 69. RUSSIA URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 70. SAUDI ARABIA URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 71. SOUTH AFRICA URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 72. SPAIN URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 73. UNITED ARAB EMIRATES URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 74. UNITED KINGDOM URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 75. GLOBAL URINARY TRACT INFECTION MARKET: FPNV POSITIONING MATRIX
  • FIGURE 76. GLOBAL URINARY TRACT INFECTION MARKET: SHARE, BY QUADRANT, 2020
  • FIGURE 77. GLOBAL URINARY TRACT INFECTION MARKET: SHARE, BY COMPANY, 2020
  • FIGURE 78. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL URINARY TRACT INFECTION MARKET, BY TYPE

LIST OF TABLES

  • TABLE 1. GLOBAL URINARY TRACT INFECTION MARKET: MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
  • TABLE 3. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 4. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY AMINOGLYCOSIDES, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 5. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY AZOLES, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 6. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY QUINOLONES, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 7. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY B-LACTAM, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 8. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 9. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CYSTITIS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 10. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PYELONEPHRITIS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 11. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY URETHRITIS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 12. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 13. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY HOSPITALS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 14. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY SELF-ADMINISTERED, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 15. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 16. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 17. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 18. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 19. ARGENTINA URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 20. ARGENTINA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 21. ARGENTINA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 22. BRAZIL URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 23. BRAZIL URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 24. BRAZIL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 25. CANADA URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 26. CANADA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 27. CANADA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 28. MEXICO URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 29. MEXICO URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 30. MEXICO URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 31. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 32. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 33. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 34. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 35. CALIFORNIA URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 36. CALIFORNIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 37. CALIFORNIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 38. FLORIDA URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 39. FLORIDA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 40. FLORIDA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 41. ILLINOIS URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 42. ILLINOIS URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 43. ILLINOIS URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 44. NEW YORK URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 45. NEW YORK URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 46. NEW YORK URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 47. OHIO URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 48. OHIO URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 49. OHIO URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 50. PENNSYLVANIA URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 51. PENNSYLVANIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 52. PENNSYLVANIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 53. TEXAS URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 54. TEXAS URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 55. TEXAS URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 56. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 57. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 58. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 59. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 60. CHINA URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 61. CHINA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 62. CHINA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 63. INDIA URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 64. INDIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 65. INDIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 66. INDONESIA URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 67. INDONESIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 68. INDONESIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 69. JAPAN URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 70. JAPAN URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 71. JAPAN URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 72. MALAYSIA URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 73. MALAYSIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 74. MALAYSIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 75. PHILIPPINES URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 76. PHILIPPINES URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 77. PHILIPPINES URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 78. SOUTH KOREA URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 79. SOUTH KOREA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 80. SOUTH KOREA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 81. THAILAND URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 82. THAILAND URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 83. THAILAND URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 88. FRANCE URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 89. FRANCE URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 90. FRANCE URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 91. GERMANY URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 92. GERMANY URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 93. GERMANY URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 94. ITALY URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 95. ITALY URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 96. ITALY URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 97. NETHERLANDS URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 98. NETHERLANDS URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 99. NETHERLANDS URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 100. QATAR URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 101. QATAR URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 102. QATAR URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 103. RUSSIA URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 104. RUSSIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 105. RUSSIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 106. SAUDI ARABIA URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 107. SAUDI ARABIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 108. SAUDI ARABIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 109. SOUTH AFRICA URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 110. SOUTH AFRICA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 111. SOUTH AFRICA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 112. SPAIN URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 113. SPAIN URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 114. SPAIN URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 115. UNITED ARAB EMIRATES URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 116. UNITED ARAB EMIRATES URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 117. UNITED ARAB EMIRATES URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 118. UNITED KINGDOM URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 119. UNITED KINGDOM URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 120. UNITED KINGDOM URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 121. GLOBAL URINARY TRACT INFECTION MARKET: SCORES
  • TABLE 122. GLOBAL URINARY TRACT INFECTION MARKET: BUSINESS STRATEGY
  • TABLE 123. GLOBAL URINARY TRACT INFECTION MARKET: PRODUCT SATISFACTION
  • TABLE 124. GLOBAL URINARY TRACT INFECTION MARKET: RANKING
  • TABLE 125. GLOBAL URINARY TRACT INFECTION MARKET: SHARE, BY QUADRANT, 2020
  • TABLE 126. GLOBAL URINARY TRACT INFECTION MARKET: SHARE, BY COMPANY, 2020
  • TABLE 127. GLOBAL URINARY TRACT INFECTION MARKET: MERGER & ACQUISITION
  • TABLE 128. GLOBAL URINARY TRACT INFECTION MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
  • TABLE 129. GLOBAL URINARY TRACT INFECTION MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
  • TABLE 130. GLOBAL URINARY TRACT INFECTION MARKET: INVESTMENT & FUNDING
  • TABLE 131. GLOBAL URINARY TRACT INFECTION MARKET: AWARD, RECOGNITION, & EXPANSION
  • TABLE 132. GLOBAL URINARY TRACT INFECTION MARKET: LICENSE & PRICING
  • TABLE 133. GLOBAL URINARY TRACT INFECTION MARKET: CONTACT DETAILS